Background: Treatment guidelines for stage II and III rectal cancer include neoadjuvant chemoradiotherapy, surgery and postoperative adjuvant chemotherapy. Although data support this recommendation in younger patients, it is unclear whether this benefit can be extrapolated to elderly patients (aged 75 years or older). 
Introduction
Cancer remains the second most common cause of death in people aged 75 years and over worldwide 1 . Although deaths from colorectal cancer have stabilized in many western and northern European countries, colorectal cancer remains the third most common cancer worldwide, and 37 per cent of all colorectal cancers occur in people aged 75 years or more 2, 3 . As the proportion of people aged at least 75 years increases, the number of elderly patients with rectal cancer is likely to continue to increase 4 -6 . Healthy individuals over the age of 75 years can expect to live another 10 years, and even those with colorectal cancer can anticipate a life expectancy of more than 5 years 7, 8 . Therefore, surgeons are increasingly faced with treating elderly patients with rectal cancer. The drive to treat these patients aggressively is supported by the current US, UK and European national treatment guidelines for locally advanced rectal cancer, which all recommend neoadjuvant chemoradiotherapy followed by surgery with curative intent and postsurgical adjuvant chemotherapy 9 -11 . Rectal cancer is predominately a disease of the elderly, and 70 per cent of those affected present with stage II-III disease 12, 13 . Therefore, determining the optimal management strategy for elderly patients with stage II and III disease is crucial.
There is a clear survival benefit of neoadjuvant and postresection adjuvant therapy for younger patients with stage II and III rectal cancer 14 -16 . However, the median Multimodal therapy for elderly patients with rectal cancer e107 age in these studies was 58-69 years, and it is unclear whether these findings can be extrapolated to patients aged 75 years or more 17 -23 . Studies 24 -26 have shown that adjuvant therapies in the elderly can significantly decrease quality of life. Patients aged 75 years and over have an increased risk of morbidity compared with younger patients, probably because they have an average of five other medical conditions at the time of diagnosis of colorectal cancer, and the rate of co-morbidities in this group is increasing 27 -30 . This partially explains why only half of elderly patients receive the recommended treatment for stage III rectal cancer 31, 32 . Unfortunately, it is often difficult to determine why these patients do not receive additional therapy from national database studies.
As the burden of cancer in the elderly population continues to increase around the world it is important continually to reassess whether current recommended treatment regimens are beneficial 33 -35 . This study assessed whether a clinically significant survival was associated with neoadjuvant and/or adjuvant therapy together with potentially curative resection of stage II and III rectal cancer in patients aged at least 75 years.
Methods
As a National Cancer Institute-designated Cancer Center, Mayo Clinic in Rochester, Minnesota, maintains a prospective tumour registry. After obtaining institutional review board approval, all patients aged 75 years and above with stage II and III rectal carcinoma, who underwent surgery with curative intent at this centre between 1996 and 2013, were identified. Patients undergoing palliative surgery were excluded.
Data from medical records were used to confirm and update findings from the tumour registry. Follow-up information was also updated through annually mailed surveys. Operative details and information regarding the triage of patients to one therapy group or another was captured when available. The Charlson/Deyo Co-morbidity Index (CCI) score was calculated, with a score of 0 indicating no co-morbid conditions recorded, 1 indicating one co-morbid condition, and 2 or above indicating the appropriate number of co-morbid conditions. The primary outcome was overall survival.
Practice standards at this institution have followed the National Institutes of Health guidelines, which were first reported in 1990 14 , and subsequently the National Comprehensive Cancer Network (NCCN) guidelines 36 published in 1996. In accordance with the sixth edition of the American Joint Committee on Cancer (AJCC) TNM system 37 , radiotherapy and concomitant 5-fluorouracil chemotherapy are offered routinely to all patients with stage II or III rectal cancer. Patients who do not receive chemoradiotherapy either decline treatment, have medical contraindications to radiotherapy, develop postoperative complications leading to no treatment, or are deemed too ill to tolerate irradiation and chemotherapy. Of note, eight patients in the present study were not offered neoadjuvant radiation because of a history of irradiation to the pelvis, but standard practice is to recommend additional radiotherapy even if the patient has been irradiated previously. Adjuvant chemotherapy is advised in all patients after successful surgical recovery, generally consisting of eight cycles of an oxaliplatin-based regimen.
To evaluate the effect of additional therapy, patients who received any therapy in addition to surgery were grouped and compared with those who received surgery alone. In the additional therapy group, a comparison was made between patients who received neoadjuvant chemoradiotherapy followed by surgery with curative intent, and those who had surgery first followed by postresection adjuvant chemotherapy.
Statistical analysis
Normally distributed data, expressed as mean(s.d.), were examined with the Student's t test. Non-normally distributed data, presented as median (i.q.r.), were analysed by means of the Mann-Whitney U test. Fisher's exact test was used to examine categorical variables. Survival analysis was performed using the method of Kaplan and Meier, with survival defined as time from diagnosis to death or censoring. Patients were censored at the date of last correspondence or follow-up. Survival curves were compared with the log rank test. To estimate the independent effect of treatment group on survival, a Cox proportional hazards model was developed, which included treatment group, CCI score, tumour location, year of diagnosis, tumour grade and operation type. P < 0⋅050 was considered statistically significant for all comparisons. Statistical analysis was performed with R version 3.0.3 (R Foundation for Statistical Computing, Vienna, Austria).
Results

Overall outcomes
The study included 160 patients aged at least 75 years who underwent surgery with curative intent for stage II (66) or III (94) rectal cancer between 1996 and 2013. Median age at diagnosis was 80 (range 75-93, i.q.r. 77-83) years, and 85⋅6 per cent were Caucasian. Procedures performed were abdominoperineal resection (85, 53⋅1 per cent), low anterior resection (70, 43⋅8 per cent) and coloanal anastomosis A higher proportion of patients with stage III disease were aged 75-80 years (68 per cent versus 47 per cent for stage II; P = 0⋅015), but sex, race, CCI score, year of diagnosis, margin-positive rate, tumour grade, tumour location, procedure and approach were similar in the two stage groups ( Table 1) .
Comparing all patients who received any additional therapy with those who had surgery alone, those in the additional therapy group were more likely to have high-grade tumours (88 versus 71 per cent; P = 0⋅012). Age, sex, race, CCI score, year of diagnosis, tumour extent, number of positive nodes, tumour location, margin-positive rate, procedure and approach were similar in the two groups ( 
Stage II rectal cancer outcomes
Kaplan-Meier analysis showed no significant difference in survival distribution curves for elderly patients with stage II disease who received neoadjuvant therapy compared with those who did not have preoperative treatment (Fig. 1a) , or for patients who received postresection adjuvant therapy compared with those who did not (Fig. 1b) . Any additional therapy, regardless of type or timing, did not show a statistically significant survival benefit, but the survival curves did separate (60-month survival 55 versus 38 per cent respectively for any additional therapy versus surgery alone; P = 0⋅184) (Fig. 1c) . A conditional survival analysis excluding patients who died within 12 months of surgery also failed to show a benefit of any additional therapy (versus surgery alone) in patients with stage II disease (P = 0⋅163).
Stage III rectal cancer outcomes
For elderly patients with stage III rectal cancer, there was improved overall survival for those who received neoadjuvant therapy compared with those who did not (Fig. 2a) . A similar survival benefit was noted for patients with stage III who received adjuvant therapy compared with those who did not have postresection therapy (Fig. 2b) .
Patients who received any adjuvant therapy, regardless of type or timing, had significantly better survival than those who underwent surgery alone (60-month survival 58 versus 30 per cent respectively; P = 0⋅007) (Fig. 2c) .
Multivariable analysis
Multivariable analysis including all elderly patients, regardless of stage, showed that receiving any additional therapy was associated with improved survival, and a CCI score of 2 or more was an independent predictor of worse survival ( Table 3) . Increasing age also appeared to confer worse survival, but this did not reach statistical significance. The survival benefit of additional therapy was not significant in analysis of patients with stage II disease; however, increasing age was predictive of decreased survival in this subgroup ( Table 4 ). The survival benefit conferred by additional therapy in patients with stage III tumours was confirmed by multivariable analysis. 
Reasons for no additional therapy
Across stage II and III rectal cancers, 48 patients (30⋅0 per cent) received neoadjuvant chemotherapy and/or radiation (2 neoadjuvant chemotherapy only, 3 neoadjuvant radiation only, 43 both). Of the 112 patients who did not receive any neoadjuvant therapy, 69 had sufficient documentation regarding why this decision was made ( Table 5) . Not recommended was the most common reason (45 per cent) to explain why patients with stage II (14 of 32) and III (17 of 37) did not receive neoadjuvant therapy before surgical resection.
For stage II and stage III disease, 54 patients (33⋅8 per cent) received adjuvant chemotherapy and/or radiation (28 adjuvant chemotherapy only, 1 adjuvant radiation only, 25 both). Of the patients who did not have adjuvant therapy, the reasons were documented sufficiently for 65 ( Table 5) . Co-morbidity, perioperative morbidity and patient preference accounted for 27 of 34 patients with stage II disease, and all 31 patients with stage III disease not receiving any additional therapy. When considering any therapy regardless of timing, only 82 (51⋅3 per cent) of the patients had chemotherapy or radiation therapy.
There was no difference in receipt of neoadjuvant therapy by stage (74 per cent of patients with stage II and 67 per cent with stage III disease did not have neoadjuvant Values in parentheses are percentages. Forty-one patients without sufficient documentation on reason are excluded. therapy; P = 0⋅427) but there was a significant difference in receipt of adjuvant therapy (82 versus 55 per cent respectively had no adjuvant therapy; P = 0⋅005). Age, CCI score, year of diagnosis, tumour location and tumour stage were not predictive of receiving additional therapy on multivariable analysis (Table 6) . Although there was a trend towards receiving additional therapy in patients operated on between 2003 and 2008 in the adjusted analysis (odds ratio 1⋅82, 95 per cent c.i. 0⋅99 to 3⋅48; P = 0⋅053), the proportion receiving any additional therapy did not appear to change over the course of the study (Fig. 3) . 
Discussion
Although standard therapy for locally advanced nonmetastatic rectal cancer under most international guidelines is neoadjuvant chemoradiotherapy followed by resection with curative intent and postresection adjuvant therapy, the data presented here suggest that neoadjuvant and postresection adjuvant chemotherapy are rarely achieved in patients aged 75 years or over. Despite this finding, the results clearly support the use of neoadjuvant chemoradiotherapy and/or postoperative adjuvant chemotherapy over surgery alone in elderly patients with stage III rectal cancer. The data for patients with stage II rectal cancer are less clear. Although no statistically significant improvement in overall survival was observed for neoadjuvant chemoradiotherapy, postoperative chemotherapy, or any therapy versus surgery alone, the survival curves are strikingly different. Adjusting for other variables in a multivariable model, the hazard ratio for additional therapy versus surgery alone is almost identical for stage II and stage III groups, suggesting that the lack of statistical significance is due to a lack of power and not a lack of clinical significance. Many studies have compared elderly with younger patients 8,25,31,38 -40 , but this is the largest single-institution study of elderly patients with stage II and III rectal cancer. A national study 32 of elderly Medicare patients showed that only a complete course of both adjuvant radiation and chemotherapy for both stage II and stage III rectal cancer decreased 5-year cancer mortality risk. However, the data presented here suggest that any adjuvant therapy is beneficial in elderly patients with stage III rectal cancer.
Interestingly, the most common reason for patients with stage II and stage III disease not receiving neoadjuvant therapy was it not being recommended by their providers. Although it is the present authors' practice to offer neoadjuvant therapy to all patients with stage II or III disease, including the elderly, they believe that undocumented frailty and concerns regarding quality of life may have contributed to this finding. More importantly, patient choice appeared to be the most common driver of not receiving postresection adjuvant therapy. Co-morbidities were the least commonly cited reason for not receiving neoadjuvant therapy. However, co-morbidity combined with perioperative morbidity accounted for nearly 40 per cent of the patients who did not receive additional postresection therapy. This, combined with the high rates of patients declining postresection therapy, highlights the importance of offering neoadjuvant therapy in elderly patients with locally advanced rectal cancer because, regardless of provider recommendation, it appears that many are unlikely to receive postresection chemotherapy.
This study has some limitations, including its retrospective and single-institution design. Although detailed charts were available for most patients, it was not possible to ascertain the precise reason for omission of additional therapies in over half of the patients who had surgery alone. Even though multiple confounders were controlled for, selection bias is a significant limitation of the study. Subtle differences in survival in the stage-specific analysis were limited owing to the sample size. Finally, higher-risk patients and those with multiple co-morbidities tend to be referred to the authors' centre and this may limit the applicability of the findings to community practices. Regardless, age alone should not be a reason to deny patients potentially helpful neoadjuvant or adjuvant therapy.
